Canagliflozin (CANA) is a member of a novel class of antidiabetic agents, selective sodium glucose-cotransporter (SGLT)-2 inhibitors, which have been approved for the treatment of patients with type-2 diabetes mellitus (T2DM) [5]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.